Metastatic Malignant Uveal Melanoma Clinical Trial
Official title:
A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma
Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is designed
to interfere with the multiplication of cancer cells, which may slow or stop their growing
and spreading throughout the body. This may cause the cancer cells to die. Liposomal
vincristine is formed when vincristine is placed inside of oil droplets called liposomes,
which may help to improve the delivery of drug to the tumor site. The liposomal formulation
results in a slow, steady release of vincristine in the tumor metastasis, exposing the cancer
cells to vincristine continuously.
The goal of this clinical research study is to learn if Marqibo (liposomal vincristine) can
help to control metastatic uveal melanoma. The safety of liposomal vincristine will also be
studied.
Approximately 50 patients will take part in this study.
n/a